Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Liabilities and Shareholders Equity (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Liabilities and Shareholders Equity readings, the most recent being $27.1 million for Q4 2023.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 19.78% to $27.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was $137.5 million, a 41.74% decrease, with the full-year FY2023 number at $27.1 million, up 19.78% from a year prior.
  • Liabilities and Shareholders Equity hit $27.1 million in Q4 2023 for Elicio Therapeutics, down from $31.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $139.2 million in Q1 2021 to a low of $22.7 million in Q4 2022.
  • Median Liabilities and Shareholders Equity over the past 4 years was $61.3 million (2022), compared with a mean of $68.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 103.84% in 2021 and later plummeted 76.52% in 2022.
  • Elicio Therapeutics' Liabilities and Shareholders Equity stood at $47.3 million in 2020, then skyrocketed by 103.84% to $96.5 million in 2021, then crashed by 76.52% to $22.7 million in 2022, then rose by 19.78% to $27.1 million in 2023.
  • The last three reported values for Liabilities and Shareholders Equity were $27.1 million (Q4 2023), $31.0 million (Q3 2023), and $37.6 million (Q2 2023) per Business Quant data.